Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Retrospective single-center study of 87 patients identifying progression patterns as prognostic factors for post-progression survival in CDK4/6-inhibitor-treated HR+/HER2− metastatic breast cancer, with statistically significant hazard ratios for visceral and liver progression but limited by design and sample size.
Real-world observational study reporting descriptive testing patterns and mutation prevalence without a comparator or causal inference; provides practice-relevant epidemiology but limited mechanistic or interventional evidence.
Retrospective single-center cohort confirming that CDK4/6 inhibitors with endocrine therapy produce PFS and OS outcomes consistent with pivotal trials in HR+/HER2− metastatic breast cancer, but lacks the design rigor and sample size for practice guidance beyond established use.
A randomized controlled trial with a clear efficacy signal (higher ORR and pCR with dual-targeted therapy) and favorable tumor marker reduction, but with surrogate endpoints and no hard clinical outcomes reported.
In vitro mechanistic study of a small molecule binding to mutant p53 domains, with no cell-based or clinical data, raising a question about therapeutic potential rather than demonstrating it.
A methodologically sound single-centre internal validation study of prognostic nomograms with good discrimination (C-index 0.74–0.76) in a contemporary HER2-positive metastatic cohort, but limited by lack of specific treatment annotation and short median follow-up relative to the 5-year outcome estimates.
Mechanistic study in genetically engineered mouse models identifying EED as a regulator of SCLC identity and LUAD-to-SCLC transformation; lacks clinical trial data or human validation beyond xenograft correlation.
A narrative review summarizing mechanistic theories of ADC resistance in bladder cancer; raises questions about resistance pathways rather than testing them empirically.